Tovecimig clinical trials
Also written CTX-009.
How each study uses tovecimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tovecimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
Compass Therapeutics (2) · Washington University School of Medicine (2) · ABL Bio, Inc. (1) · M.D. Anderson Cancer Center (1) · Elpiscience (Suzhou) Biopharma, Ltd. (1) · Handok Inc. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tovecimig, phase 3 first.
- Aug 2027A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Phase 2/3 · Compass Therapeutics
- May 2027CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses tovecimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07662031Written as Tovecimig
- CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06548412Written as CTX-009
- Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent GlioblastomaRecruitingPhase 1/2Washington University School of MedicineNCT07392957Written as CTX-009
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Active, not recruitingPhase 2/3Compass TherapeuticsNCT05506943Written as CTX-009
- A Study of ES104 in Patients With Metastatic Colorectal CancerTerminatedPhase 1/2Elpiscience (Suzhou) Biopharma, Ltd.NCT05167448Written as ES104
- A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerCompletedPhase 2Compass TherapeuticsNCT05513742Written as CTX-009
- A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor PatientsTerminatedPhase 1/2Handok Inc.NCT04492033Written as CTX-009 (ABL001)
- This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001CompletedPhase 1ABL Bio, Inc.NCT03292783Written as NOV1501 (ABL001)
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- A Study of ES104 in Patients With Metastatic Colorectal CancerTerminatedOct 26, 2026NCT05167448
Codes
What other systems call tovecimig · ClinicalTrials.gg INT018628
- UNII (FDA) YXM6C5LQ2HTOVECIMIGOne source FDA
- NCI Thesaurus C185865TovecimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YXM6C5LQ2H | TOVECIMIG | One source FDA |
| NCI Thesaurus | C185865 | Tovecimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.